Advances in gene therapy for ADA-deficient SCID

Current Opinion in Molecular Therapeutics

Volumn 4, Issue 5, 2002, Pages 515-522

  Aiuti, Alessandro ^a  

^a SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Adenosine deaminase; Gene transfer; Hemotopoietic stem cells; Peripheral blood lymphocytes; Primary immunodeficiency; Retroviral vector

Indexed keywords

ADENOSINE; ADENOSINE DEAMINASE; BUSULFAN; CD34 ANTIGEN; COMPLEMENTARY DNA; CYTOKINE; DEOXYADENOSINE; DEOXYADENOSINE TRIPHOSPHATE; FIBRONECTIN; FLT3 LIGAND; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; MACROGOL; MONOCLONAL ANTIBODY CD3; NEOMYCIN; NUCLEOTIDE; PHYTOHEMAGGLUTININ; PURINE; RETRONECTIN; RETROVIRUS VECTOR; STEM CELL FACTOR; THROMBOPOIETIN; UNCLASSIFIED DRUG;

B LYMPHOCYTE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG EFFICACY; DRUG SAFETY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; ERYTHROCYTE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC CODE; GENETIC DISORDER; GENETIC TRANSDUCTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC SYSTEM; HUMAN; IMMUNOPATHOLOGY; INFECTION; METABOLIC DISORDER; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; PERIPHERAL LYMPHOCYTE; PILOT STUDY; PROMOTER REGION; PURINE METABOLISM; REVIEW; SIMIAN VIRUS 40; T LYMPHOCYTE;

ADENOSINE DEAMINASE; GENE THERAPY; HUMANS; SEVERE COMBINED IMMUNODEFICIENCY;

ADA; MOLONEY MURINE LEUKEMIA VIRUS; ONCOVIRINAE; SIMIAE; SIMIAN VIRUS 40; UNIDENTIFIED RETROVIRUS;

EID: 0036819746     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ et al: T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science (1995) 270:475-480.
2. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P, Ugazio AG et al: Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science (1995) 270:470-475.
3. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, el Khoureiy A, Lawrence K et al: Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med (1995) 1:1017-1023.
4. Hirschhorn R: Immunodeficiency disease due to deficiency of adenosine deaminase. In: Primary Immunodeficiency Diseases. Ochs H, Smith C, Puck J (Eds), Oxford University Press, Oxford, UK (1999):121-139.
5. Ferrari G, Rossini S, Giavazzi R, Maggioni D, Nobili N, Soldati M, Ungers G, Mavilio F, Gilboa E, Bordignon C: An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science (1991) 251:1363-1366.
6. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, Bousso P et al: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science (2000) 288:669-672.
7. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, Morecki S, Andolfi G, Tabucchi A, Carlucci F, Marinello E et al: Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science (2002) 296:2410-2413.
8. Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, Andolfi G, Ferrari G, Tabucchi A, Carlucci F, Ochs HD, Notarangelo LD et al: Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med (2002) 8:423-425.
9. Hershfield MS: Adenosine deaminase deficiency: Clinical expression, molecular basis, and therapy. Semin Hematol (1998) 35:291-298.
10. Resta R, Thompson LF: SCID: The role of adenosine deaminase deficiency. Immunol Today (1997) 18:371-374.
11. Arredondo-Vega F, Santisteban I, Daniels S, Toutain S, Hershfield MS: Adenosine deaminase deficiency: Genotype-phenotype correlations based on expressed activity of 29 mutant alleles. Am J Hum Genet (1998) 63:1049-1059.
12. Blackburn MR, Volmer JB, Thrasher JL, Zhong H, Crosby JR, Lee JJ, Kellems RE: Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction. J Exp Med (2000) 192:159-170.
13. Ratech H, Hirschhorn R, Greco MA: Pathologic findings in adenosine deaminase deficient-severe combined immunodeficiency. II. Thymus, spleen, lymph node, and gastrointestinal tract lymphoid tissue alterations. Am J Pathol (1989) 135:1145-1156.
14. Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB: Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr (2001) 139:44-50.
15. Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana CM, Morgan G, Bertrand Y, Fasth A, Porta F, Cant A, Espanol T et al: Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective study of 116 patients. Blood (1998) 91:3646-3653.
16. Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL, Myers LA, Ward FE: Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med (1999) 340:508-516.
17. Amrolia P, Gaspar HB, Hassan A, Webb D, Jones A, Sturt N, Mieli-Vergani G, Pagliuca A, Mufti G, Hadzic N, Davies G et al: Nonmyeloablative stem cell transplantation for congenital immunodeficiencies. Blood (2000) 96:1239-1246.
18. Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen FS: Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest (1981) 68:1387-1393.
19. Ochs HD, Buckley RH, Kobayashi RH, Kobayashi AL, Sorensen RU, Douglas SD, Hamilton BL, Hershfield MS: Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiency. Blood (1992) 80:1163-1171.
20. Kantoff PW, Kohn DS, Mitsuya H, Armentano D, Sieberg M, Zwiebel JA, Eglitis MA, McLachlin JR, Wiginton DA, Hutton JJ, Horowitz S et al: Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci USA (1986) 83:6563-6567.
21. Blaese M, Anderson F, Culver K, Rosenberg S: The ADA human gene therapy clinical protocol. Hum Gene Ther (1990) 1:327-362.
22. Bordignon C, Mavilio F, Ferrari G, Servida P, Ugazio AG, Notarangelo LD, Gilboa E, Rossini S, O'Reilly RJ, Smith CA et al: Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. Hum Gene Ther (1993) 4:513-520.
23. Hirschhorn R, Yang DR, Puck JM, Huie ML, Jiang CK, Kurlandsky LE: Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat Genet (1996) 13:290-295.
24. Ariga T, Oda N, Yamaguchi K, Kawamura N, Kikuta H, Taniuchi S, Kobayashi Y, Terada K, Ikeda H, Hershfield MS, Kobayashi K et al: T-cell lines from 2 patients with adenosine deaminase (ADA) deficiency showed the restoration of ADA activity resulted from the reversion of an inherited mutation. Blood (2001) 97:2896-2899.
25. Hoogerbrugge PM, van Beusechem VW, Fischer A, Debree M, le Deist F, Perignon JL, Morgan G, Gaspar B, Fairbanks LD, Skeoch CH, Moseley A et al: Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther (1996) 3:179-183.
26. Bordignon C, Roncarolo MG: Therapeutic applications for hematopoietic stem cell gene transfer. Nat Immunol (2002) 3:318-321.
27. Onodera M, Ariga T, Kawamura N, Kobayashi I, Ohtsu M, Yamada M, Tame A, Furuta H, Okano M, Matsumoto S, Kotani H et al: Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood (1998) 91:30-36.
28. Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM, Barsky LW, Chan R, Burotto F, Annett G, Nolta JA et al: T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med (1998) 4:775-780.
29. Murray L, Luens K, Tushinski R, Jin L, Burton M, Chen J, Forestell S, Hill B: Optimization of retroviral gene transduction of mobilized primitive hematopoietic progenitors by using thrombopoietin, Flt3, and Kit ligands and RetroNectin culture. Hum Gene Ther (1999) 10:1743-1752.
30. Glimm H, Eaves CJ: Direct evidence for multiple self-renewal divisions of human in vivo repopulating hematopoietic cells in short-term culture. Blood (1999) 94:2161-2168.
31. Abonour R, Williams DA, Einhorn L, Hall KM, Chen J, Coffman J, Traycoff CM, Bank A, Kato I, Ward M, Williams SD et al: Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med (2000) 6:652-658.
32. Dunbar CE, Takatoku M, Donahue RE: The impact of ex vivo cytokine stimulation on engraftment of primitive hematopoietic cells in a non-human primate model. Ann NY Acad Sci (2001) 938:236-244.
33. Dando JS, Aiuti A, Deola S, Ficara F, Bordignon C: Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+ cells. J Gene Med (2001) 3:219-227.
34. Roncarolo MG, Carballido JM, Rouleau M, Namikawa R, de Vries JE: Human T-and B-cell functions in SCID-hu mice. Semin Immunol (1996) 8:207-213.
35. Williams DA: Retroviral-fibronectin interactions in transduction of mammalian cells. Ann NY Acad Sci (1999) 872:109-113.
36. Barquinero J, Kiem HP, von Kalle C, Darovsky B, Goehle S, Graham T, Seidel K, Storb R, Schuening FG: Myelosuppressive conditioning improves autologous engraftment of genetically marked hematopoietic repopulating cells in dogs. Blood (1995) 85:1195-1201.
37. Huhn RD, Tisdale JF, Agricola B, Metzger ME, Donahue RE, Dunbar CE: Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum Gene Ther (1999) 10:1783-1790.
38. Rosenzweig M, MacVittie TJ, Harper D, Hempel D, Glickman RL, Johnson RP, Farese AM, Whiting-Theobald N, Linton GF, Yamasaki G, Jordan CT et al: Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood (1999) 94:2271-2286.
39. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood (1998) 91:756-763.
40. Bolinger AM, Zangwill AB, Slattery JT, Glidden D, DeSantes K, Heyn L, Risler LJ, Bostrom B, Cowan MJ: An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant (2000) 25:925-930.
41. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A et al: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med (2002) 346:1185-1193.
42. Fischer A, Landais P, Friedrich W, Morgan G, Gerritsen B, Fasth A, Porta F, Griscelli C, Goldman SF, Levinsky R et al: European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet (1990) 336:850-854.
43. Onodera M, Nelson DM, Yachie A, Jagadeesh GJ, Bunnell BA, Morgan RA, Blaese RM: Development of improved adenosine deaminase retroviral vectors. J Virol (1998) 72:1769-1774.
44. Kay MA, Glorioso JC, Naldini L: Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 7:33-40.